Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients infected with HIV.
Substitution of a non-nucleoside reverse transcriptase inhibitor (NNRTI) with another drug of the same class combined with nucleoside reverse transcriptase inhibitors is a therapeutic strategy that can improve the tolerability of antiretroviral treatment. According to the pharmacokinetic properties of NNRTIs, this substitution generates pharmacokinetic drug interactions between NNRTIs, which could decrease NNRTI exposure and virological efficacy during the introductory phase of the new NNRTI. Pharmacokinetics and clinical data are reviewed to estimate the risk for switching from efavirenz to nevirapine, efavirenz to etravirine, efavirenz to rilpivirine and nevirapine to rilpivirine.
Eric
E
Dailly
Clotilde
C
Allavena
Guillaume
G
Deslandes
Regis
R
Bouquie
Pascale
P
Jolliet
Laboratoire de Pharmacologie Clinique, Hotel Dieu, 9 Quai Moncousu, 44093 Nantes Cedex, France. eric.dailly@chu-nantes.fr.
Francois
F
Raffi
D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D004347:Drug Interactions; D057915:Drug Substitution; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors